Medindia

X

CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference

Thursday, February 14, 2008 General News J E 4
Advertisement
ATLANTA, Feb. 13 CryoLife, Inc. (NYSE: CRY), abiomaterials, medical device and tissue processing company, announced todaythat it is scheduled to participate in the Roth Capital Partners 20th AnnualOC Growth Stock Conference, February 19, 2008 at the Ritz Carlton LagunaNiguel in Dana Point, Calif.

D. Ashley Lee, executive vice president, chief operating officer and chieffinancial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30a.m., Pacific Time.

CryoLife's live presentation may be accessed through its Web site,www.cryolife.com, on the Investor Relations page. An archived copy of thepresentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing anddistribution of implantable living human tissues for use in cardiac andvascular surgeries throughout the United States and Canada. The Companyrecently received FDA clearance for its CryoValve(R) SG pulmonary human heartvalves, processed using CryoLife's proprietary SynerGraft(R) Technology. TheCompany's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct tosutures and staples for use in adult patients in open surgical repair of largevessels. BioGlue is also CE marked in the European Community and approved inCanada and Australia for use in soft tissue repair. The Company alsodistributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CEmarked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web Site:http://www.cryolife.com.Media Contacts: D. Ashley Lee Katie Brazel Executive Vice President, Chief Financial Officer Fleishman Hillard and Chief Operating Officer Phone: 770-419-3355 Phone: 404-739-0150

SOURCE CryoLife, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Genzyme Delivers Strong Fourth Quarter to Conclude...
S
The Female Health Company Reports 37% Revenue Grow...